Metformin has been shown to inhibit NLRP3 inflammasome activation via AMPK-dependent mechanisms in kidney injury models, reducing IL-1β and TNF-α release and ameliorating renal inflammation in diabetic nephropathy and CKD contexts [64,65]. The gene discussed is NLRP3; the disease is chronic kidney disease.